OTCMKTS:ENZN

Enzon Pharmaceuticals (ENZN) Stock Price, News & Analysis

Enzon Pharmaceuticals logo
$4.35 0.00 (0.00%)
As of 11/17/2026

About Enzon Pharmaceuticals Stock (OTCMKTS:ENZN)

Advanced

Key Stats

Today's Range
$4.35
▼
$4.35
50-Day Range
$4.35
▼
$4.35
52-Week Range
$1.50
▼
$9.50
Volume
N/A
Average Volume
1,513 shs
Market Capitalization
$3.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Enzon Pharmaceuticals is a biotechnology company best known for developing medicines that use PEGylation, a process that attaches polyethylene glycol to a drug to alter its properties. Its historical work focused on treatments for cancer and rare diseases.

Products associated with Enzon include Adagen, Oncaspar and Sylatron. The company also developed PEG-Intron with Schering-Plough. These products and related rights were later sold or licensed, including the sale of Enzon’s oncology therapeutics business to Sigma-Tau in 2013.

Enzon’s former drug-development and product portfolio should not be taken as a description of an active commercial business today. The company’s operations and assets changed substantially through divestitures; reliable information about current products, geographic markets or leadership is limited.

AI Generated. May Contain Errors.

Receive ENZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ENZN Stock News Headlines

Viskase Holdings (ENZN) Ratios
I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
Enzon Pharmaceuticals Inc.
See More Headlines

ENZN Stock Analysis - Frequently Asked Questions

Enzon Pharmaceuticals' stock was trading at $3.78 at the beginning of 2026. Since then, ENZN stock has increased by 15.1% and is now trading at $4.35.

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) posted its earnings results on Monday, May, 4th. The biotechnology company reported ($0.84) earnings per share for the quarter. The biotechnology company earned $86.54 million during the quarter.

Enzon Pharmaceuticals's stock reverse split on the morning of Friday, April 3rd 2026.The 1-100 reverse split was announced on Friday, April 3rd 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 3rd 2026. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of ENZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enzon Pharmaceuticals investors own include Medical Marijuana (MJNA), BioCryst Pharmaceuticals (BCRX), Micron Technology (MU), Bausch Health Cos (BHC), Civeo (CVEO), GE Aerospace (GE) and Anthera Pharmaceuticals (ANTH).

Company Calendar

Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:ENZN
Previous Symbol
NASDAQ:ENZN
CIK
727510
Employees
N/A
Year Founded
1981

Profitability

EPS (Trailing Twelve Months)
($6.84)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.41 million
Net Margins
N/A
Pretax Margin
6.52%
Return on Equity
-21.54%
Return on Assets
-7.22%

Debt

Debt-to-Equity Ratio
0.42
Current Ratio
2.01
Quick Ratio
1.16

Sales & Book Value

Annual Sales
$30 thousand
Price / Sales
107.59
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.40) per share
Price / Book
-1.28

Miscellaneous

Outstanding Shares
742,000
Free Float
739,000
Market Cap
$3.23 million
Optionable
Not Optionable
Beta
-0.05

Social Links

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (OTCMKTS:ENZN) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners